Rodent models of tumours of the central nervous system

被引:1
|
作者
Brandner, Sebastian [1 ,2 ]
机构
[1] UCL Queen Sq Inst Neurol, Dept Neurodegenerat Dis, Queen Sq,Queen Sq House, London WC1N 3BG, England
[2] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, NHS Fdn Trust, Div Neuropathol, Queen Sq House,Queen Sq, London WC1N 3BG, England
关键词
brain tumour; Cre-lox system; CRISPR Cas9 system; genetically modified mouse model; glioblastoma; medulloblastoma; SITE-SPECIFIC RECOMBINATION; NEURAL STEM-CELLS; PRIMITIVE NEUROECTODERMAL TUMORS; MUTAGENESIS IDENTIFIES GENES; CHOROID-PLEXUS TUMORS; PEDIATRIC HIGH-GRADE; HUMAN-BRAIN-TUMORS; LARGE-T-ANTIGEN; SONIC HEDGEHOG; GROWTH-FACTOR;
D O I
10.1002/1878-0261.13729
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Modelling of human diseases is an essential component of biomedical research, to understand their pathogenesis and ultimately, develop therapeutic approaches. Here, we will describe models of tumours of the central nervous system, with focus on intrinsic CNS tumours. Model systems for brain tumours were established as early as the 1920s, using chemical carcinogenesis, and a systematic analysis of different carcinogens, with a more refined histological analysis followed in the 1950s and 1960s. Alternative approaches at the time used retroviral carcinogenesis, allowing a more topical, organ-centred delivery. Most of the neoplasms arising from this approach were high-grade gliomas. Whilst these experimental approaches did not directly demonstrate a cell of origin, the localisation and growth pattern of the tumours already pointed to an origin in the neurogenic zones of the brain. In the 1980s, expression of oncogenes in transgenic models allowed a more targeted approach by expressing the transgene under tissue-specific promoters, whilst the constitutive inactivation of tumour suppressor genes ('knock out')-often resulted in embryonic lethality. This limitation was elegantly solved by engineering the Cre-lox system, allowing for a promoter-specific, and often also time-controlled gene inactivation. More recently, the use of the CRISPR Cas9 technology has significantly increased experimental flexibility of gene expression or gene inactivation and thus added increased value of rodent models for the study of pathogenesis and establishing preclinical models. We describe the evolution of experimental systems, illustrated here in a timeline to show changing popularity over time. Starting with chemical and viral carcinogenesis, systems then developed into increasingly sophisticated genetically modified animal models. The literature cited in this article corresponds to the arrows in this illustration and the schematics illustrate the mechanism of action described in this article. image
引用
收藏
页码:2842 / 2870
页数:29
相关论文
共 50 条
  • [41] The special type of mesenchyme tumours of the central nervous system
    Awzen, AP
    ACTA MEDICA SCANDINAVICA, 1935, 87 : 470 - 486
  • [42] Neuroimaging to diagnose central nervous system tumours in children
    Cheng, Sylvia
    Goldman, Ran D.
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (03) : 165 - 167
  • [43] CENTRAL NERVOUS SYSTEM TUMOURS IN INFANTS AND EARLY CHILDHOOD
    Trivedi, M.
    Goodden, J.
    Chumas, P.
    Tyagi, A.
    O'Kane, R.
    Crimmins, D.
    Picton, S.
    Elliott, M.
    NEURO-ONCOLOGY, 2012, 14 : 48 - 48
  • [44] Childhood central nervous system tumours in Ibadan, Nigeria
    Babatunde, T. O.
    Ogun, G. O.
    Adeleye, A. O.
    Brown, B. J.
    Akang, E. E.
    HISTOPATHOLOGY, 2012, 61 : 175 - 176
  • [45] Molecular pathology of paediatric central nervous system tumours
    Chiang, Jason C. H.
    Ellison, David W.
    JOURNAL OF PATHOLOGY, 2017, 241 (02): : 159 - 172
  • [46] Impact of war on central nervous system tumours incidence
    Telarovic, S.
    Telarovic, S.
    Relja, M.
    Franinovic-Markovic, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 312 - 312
  • [47] The 2021 WHO classification of tumours of the central nervous system
    Figarella-Branger, Dominique
    Appay, Romain
    Metais, Alice
    Tauziede-Espariat, Arnault
    Colin, Carole
    Rousseau, Audrey
    Varlet, Pascale
    ANNALES DE PATHOLOGIE, 2022, 42 (05) : 367 - 382
  • [48] Attractin/Mahogany protein expression in the rodent central nervous system
    Nakadate, Kazuhiko
    Sakakibara, Shin-Ichi
    Ueda, Shuichi
    JOURNAL OF COMPARATIVE NEUROLOGY, 2008, 508 (01) : 94 - 111
  • [49] Immunolocalisation of epidermal surface antigen in the rodent central nervous system
    Hamscho, N
    Simbürger, E
    Savaskan, NE
    Bräuer, AU
    JOURNAL OF NEUROCHEMISTRY, 1999, 73 : S63 - S63
  • [50] Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
    DeVos, Sarah L.
    Miller, Timothy M.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2013, (75):